According to Critical Pharmaceuticals, a Phase 1b study has shown that its CP024 dry powder intranasal human growth hormone (hGH) was well tolerated with only a few minor adverse effects and showed a linear dose response. CP024 also induced production of therapeutic levels of insulin-like growth factor (IGF-1), making it the first nasal formulation of growth hormone reported to do so, the company said.
Currently, the only marketed formulations of hGH must be injected subcutaneously, Critical notes, and an estimated two thirds of patients are non-adherent to the therapy.
Critical Pharmaceuticals CEO Gareth King commented, “We are very excited about the latest clinical results with CP024 which provide clear proof of concept for this product, and which will support our search for a suitable development and commercialization partner to progress the product into phase 2/3 clinical studies. As well as providing an attractive alternative to injection, we believe CP024 may have clinical benefits by reducing circulating growth hormone levels which reduce insulin sensitivity seen with current treatments of growth hormone while maintaining therapeutic IGF-1 levels.”
Read the Critical Pharmaceuticals press release.
